Search

Your search keyword '"Richman, Douglas"' showing total 2,577 results

Search Constraints

Start Over You searched for: Author "Richman, Douglas" Remove constraint Author: "Richman, Douglas"
2,577 results on '"Richman, Douglas"'

Search Results

1. Recommendations on data sharing in HIV drug resistance research.

2. Viral and antiretroviral dynamics in HIV mother-to-child transmission fluids (VADICT) – Protocol and data analysis plan for a cohort study

3. Prevalence of detectable HIV-DNA and HIV-RNA in cerebrospinal fluid of youth with perinatal HIV and impaired cognition on antiretroviral therapy

4. Prevalence of detectable HIV-DNA and -RNA in cerebrospinal fluid of youth with perinatal HIV and impaired cognition on antiretroviral therapy

5. Immune resilience despite inflammatory stress promotes longevity and favorable health outcomes including resistance to infection

6. 2022 update of the drug resistance mutations in HIV-1.

7. Integrated proteomics and transcriptomics analyses identify novel cell surface markers of HIV latency

8. Development of the HIV360 international core set of outcome measures for adults living with HIV: A consensus process

9. Diagnostic Accuracy of Dried Plasma Spot Specimens for HIV-1 Viral Load Testing: A Systematic Review and Meta-analysis

10. Immunologic resilience and COVID-19 survival advantage.

11. Assessing the Suitability of Next-Generation Viral Outgrowth Assays to Measure Human Immunodeficiency Virus 1 Latent Reservoir Size.

12. Assessing suitability of next-generation viral outgrowth assays as proxies for classic QVOA to measure HIV-1 latent reservoir size

13. Assessing the Suitability of Next-Generation Viral Outgrowth Assays to Measure Human Immunodeficiency Virus 1 Latent Reservoir Size.

14. Disregarding drug resistance mutations without peril

15. COVID-19 vaccines: implementation, limitations and opportunities

16. Intact Human Immunodeficiency Virus (HIV) Reservoir Estimated by the Intact Proviral DNA Assay Correlates With Levels of Total and Integrated DNA in the Blood During Suppressive Antiretroviral Therapy.

17. Is France Once Again Looking for a Scapegoat?

18. Inconsistent reversal of HIV-1 latency ex vivo by antigens of HIV-1, CMV, and other infectious agents

19. Replicate Aptima Assay for Quantifying Residual Plasma Viremia in Individuals on Antiretroviral Therapy

20. Antiviral Drug Discovery To Address the COVID-19 Pandemic

21. Recommendations for measuring HIV reservoir size in cure-directed clinical trials.

22. Intact HIV reservoir estimated by the intact proviral DNA assay correlates with levels of total and integrated DNA in the blood during suppressive antiretroviral therapy.

23. Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study.

24. A case report of disseminated histoplasmosis and concurrent cryptococcal meningitis in a patient treated with ruxolitinib

25. Replication competence of virions induced from CD4+ lymphocytes latently infected with HIV

26. Recommendations on data sharing in HIV drug resistance research

27. 2019 update of the drug resistance mutations in HIV-1.

28. Myroides injenensis Bacteremia and Severe Cellulitis

29. Reply to Ambrosioni et al.

30. Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size.

31. Histone deacetylase inhibitors induce complex host responses that contribute to differential potencies of these compounds in HIV reactivation

32. Viral and antiretroviral dynamics in HIV mother-to-child transmission fluids (VADICT) – Protocol and data analysis plan for a cohort study

33. Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society–USA Panel

34. Quantitation of Integrated HIV Provirus by Pulsed-Field Gel Electrophoresis and Droplet Digital PCR

35. Improved assays to measure and characterize the inducible HIV reservoir.

36. Analytical antiretroviral therapy interruption does not irreversibly change preinterruption levels of cellular HIV

37. Antigen-specific antibody Fc glycosylation enhances humoral immunity via the recruitment of complement

38. Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size

39. Transplantation of CCR5∆32 Homozygous Umbilical Cord Blood in a Child With Acute Lymphoblastic Leukemia and Perinatally Acquired HIV Infection.

40. CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells

41. Temporal variation in HIV-specific IgG subclass antibodies during acute infection differentiates spontaneous controllers from chronic progressors

42. Factors Associated With Persistence of Plasma HIV-1 RNA During Long-term Continuously Suppressive Firstline Antiretroviral Therapy.

43. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study

44. Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc

45. Transcriptional Modulation of Human Endogenous Retroviruses in Primary CD4+ T Cells Following Vorinostat Treatment

47. A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care.

48. Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study.

49. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.

50. Immunologic resilience and COVID-19 survival advantage

Catalog

Books, media, physical & digital resources